'did not reach theraputic levels severe pain'

Whilst progress is always good, does anybody else think that the below will hold back the share-price in the short to medium term?

From today's announcement: While we did not reach the therapeutic levels required to manage very severe pain, we are confident we can achieve this in the scale-up of the weekly patch technology.

About Phosphagenics
Phosphagenics is commercialising drug delivery applications based on its novel transdermal (drugs
administered via skin) TPM Targeted Penetration Matrix technology. TPM is a patient friendly and cost
effective system used to deliver proven pharmaceutical and nutraceutcial products. The two product targets
which are advancing through clinical trials are an insulin patch for diabetics (instead of injections) and Phosphagenics shares are listed on the Australian Securities Exchange (POH) and its ADR Level 1
program in the US is with The Bank of New York Mellon (PPGNY).

So they couldnt reach the theraputic levels required to manage severe pain and one of there 2 promoted product targets (insulin currently in hiatus) is 'an
oxycodone patch for the relief of chronic pain.'

I gather that severe and chronic mean the same thing?